Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.

Brian BoylanGlenn P NiemeyerBonnie WernerConnie H Miller

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Measurement of anti-FVIII antibodies may be a useful means to better contextualize NBA results in specimens from patients receiving BPA or ITI. In addition, assessment of anti-FVIII antibody levels has the potential to improve inhibitor surveillance and clinical decision-making related to the progress of ITI.

Keyphrases

decision making
public health
risk assessment
mesenchymal stem cells
human health